Ascletis Pharma Inc (1672.HK) stock: key figures, P/E, revenue and dividend

Health Care · China · ISIN KYG0520K1094

Price
4.03 HKD
Market cap
3.96 bn HKD
P/E (2025)
–
P/S (2025)
1,951.36
Dividend yield
0.00 %
Net margin
-18,510.81 %
Return on equity (ROE)
-19.41 %
Return on assets (ROA)
-18.17 %

Ascletis Pharma Inc financials

Fiscal year20242025
Revenue1.28 m CNY2.03 m CNY
Gross profit0.00 CNY0.00 CNY
EBIT-263.03 m CNY-504.41 m CNY
Net income-300.94 m CNY-375.40 m CNY
Diluted EPS – continuing operations-0.27 CNY-0.38 CNY

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Ascletis Pharma Inc

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.